A. Holstein, H. Stege, P. Kovacs: Lipoatrophie unter dem Insulinanalogon Glargin. In: Diabetologie und Stoffwechsel. Band5, S 1, April 2010, ISSN1861-9002, S.P198, doi:10.1055/s-0030-1253926.
H.Hauner, B.Stockamp, B.Haastert: Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. In: Experimental and Clinical Endocrinology and Diabetes. Band104, Nr.2, 1996, S.106–110, doi:10.1055/s-0029-1211431.
K.Raile, V.Noelle, R.Landgraf, H.P.Schwarz: Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type I Diabetes. In: Experimental and Clinical Endocrinology and Diabetes. Band109, 2001, S.393–396, doi:10.1055/s-2001-18991.
H.J. Ziegelasch, R.Mett: Therapie einer massiven Lipohypertrophie bei Typ-1-Langzeitdiabetes. In: Diabetologie und Stoffwechsel. Nr.5, 2010, S.P96, doi:10.1055/s-0030-1253824.
H. Hauner, R. R. Olbrisch: Behandlung einer Typ-I-Diabetikerin mit insulininduzierter Lipohypertrophie durch Fettgewebssaugung. In: Deutsche Medizinische Wochenschrift. Band119, Nr.12, 1994, S.414–417, doi:10.1055/s-2008-1058709.
T. Petruschke, H. Hauner: Tumor necrosis factor-alpha prevents the differentiation of human adipocyte precursor cells and causes delipidation of newly developed fat cells. In: Journal of Clinical Endocrinology and Metabolism. Band76, Nr.3, 1993, S.742–747, doi:10.1210/jcem.76.3.844503.
E.A.Chantelau, R.Praetor, J.Praetor, L.W.Poll: Relapsing insulin-induced lipoatrophy, cured by prolonged low-dose oral prednisone: a case report. In: Diabetology & Metabolic Syndrome. Band3:33, 2011, doi:10.1186/1758-5996-3-33.
H.Hauner, G.Entenmann, M.Wabitsch, D. Gaillard, G.Ailhaud, R.Negrel, E.F.Pfeiffer: Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. In: Journal of Clinical Investigation. Band84, Nr.5, 1989, S.1663–1670, doi:10.1172/JCI114345.
A.N. Tavare, H.J. Doolittle, R. Baburaj: Pan-insulin allergy and severe lipoatrophy complicating Type 2 diabetes. In: Diabetic Medicine. Band28, Nr.4, 2011, S.500–503, doi:10.1111/j.1464-5491.2010.03196.x.
S. Ojaimi, J.P. Buttery, T.M. Korman: Quadrivalent Human Papillomavirus recombinant vaccine associated lipoatrophy. In: Vaccine. Band27, Nr.36, 2009, S.4876–4878, doi:10.1016/j.vaccine.2009.06.026.
J.A. Aviles-Izquierdo, M.I. Longo-Imedio, J.M. Hernanz-Hermosa, P. Lazaro-Ochaita: Bilateral localized lipoatrophy secondary to a single intramuscular corticosteroid injection. In: Dermatology Online Journal. Band12, Nr.3, 2006, S.17, doi:10.5070/D39gp7r8pr.
P. Touraine, G.A. D’Souza, I. Kourides, R. Abs, P. Barclay, R. Xie, A. Pico, E. Torres-Vela B. Ekman, GH Lipoatrophy Study Group: Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. In: European Journal of Endocrinology. Band161, Nr.4, 2009, S.533–540, doi:10.1530/EJE-09-0422.
A. Atmaca, T. Erbas: Lipoatrophy induced by subcutaneous administration of octreotide in the treatment of acromegaly. In: Experimental and Clinical Endocrinology and Diabetes. Band113, Nr.6, 2005, S.340–343, doi:10.1055/s-2005-837664.
A. Holstein, H. Stege, P. Kovacs: Lipoatrophie unter dem Insulinanalogon Glargin. In: Diabetologie und Stoffwechsel. Band5, S 1, April 2010, ISSN1861-9002, S.P198, doi:10.1055/s-0030-1253926.
